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S UMM A R Y
S E T T I N G : There remains a lack of effective and
inexpensive diagnostic tools for active tuberculosis
(TB) disease. Testing immune responses to proteins
secreted by Mycobacterium tuberculosis, such as
MPT64, may be a diagnostic option.
OB J E C T I V E : To evaluate the sensitivity and specificity
of a patch test using MPT64 for the diagnosis of active
TB disease.
DE S I GN : This randomised, double-blind, placebo-con-
trolled, prospective study in Lima, Peru, involved 55
healthy controls and 457 symptomatic individuals
referred for routine TB testing by the National TB
Control Programme. All subjects underwent a compre-
hensive diagnostic workup, and received an active patch
on one arm and a placebo patch on the opposite arm,
which were read after 4 days.
R E SU LT S : Eighty-one (18%) of the symptomatic par-
ticipants were classified as having definite TB, while an
additional 98 (21%) had probable TB. The patch tests
performed the same in both groups, with a sensitivity of
27% and specificity of 74%. The area under the receiver
operating characteristic curve was 0.495 (95%CI 0.425–
0.565).
CONC LU S I ON S : Contrary to existing literature, the
MPT64 patch was not sensitive and specific to detect
active TB. Given the potential of the test, understanding
possible differences in the protein source or underlying
genetic factors should be explored further.
K E Y WORD S : TB; diagnostic; MPT64; patch test
IN 2016, TUBERCULOSIS (TB) incidence was
estimated at 10.4 million cases worldwide, and
resulted in 1.3 million deaths.1 TB remains an
important global health problem, but effective
control is hampered by the lack of an effective,
inexpensive and readily scalable diagnostic tool to
distinguish between active disease, latent infection
and past exposure or vaccination. There is a need for
improvement in the diagnosis of active disease, as
delay in diagnosis both worsens the prognosis for the
individual and permits ongoing transmission in the
community.2–4
Tools currently employed to diagnose tuberculous
infection or TB disease include the tuberculin skin test
(TST) using a purified protein derivative (PPD),
sputum smear microscopy and culture, interferon-
gamma release assays (IGRAs) and molecular assays
such as Xpertw MTB/RIF (Cepheid, Sunnyvale, CA,
USA) polymerase chain reaction amplification. How-
ever, there are constraints that limit the usefulness of
each tool for diagnosing active disease. TST and
IGRAs cannot reliably distinguish between infection
and disease,5–8 while the low sensitivity of sputum
smear microscopy means it can detect only 50% of
active pulmonary cases and its limited specificity
means that Mycobacterium tuberculosis cannot be
distinguished from non-tuberculous mycobacteria
(NTM).9 Sputum culture overcomes this limitation,
but it takes at least 1 week to obtain a result and
requires a biosafety level 2 laboratory.9,10,11 Al-
though Xpert obviates the need for a laboratory and
can provide rapid detection and rifampicin suscepti-
bility results, the equipment and cartridge costs, the
fragility of the platform and the continued need for
laboratory infrastructure for downstream drug sus-
ceptibility testing impedes the sustainability and
capacity for peripheral distribution in endemic
regions.9,12–14
The MPT64 patch test was developed by Naka-
mura et al. to address the above limitations.15,16 The
test consists of a standard gauze patch with a solution
containing purified MPT64 protein. It is placed on
the volar surface on either forearm, and the skin
reaction is read after 4 days. Positive reactions consist
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of a dermal reaction to the MPT64 protein, usually
erythema, induration or small red vesicles at the patch
site. Small Phase I and Phase II studies of a patch test
by Nakamura et al. demonstrated excellent sensitivity
(.85%) and specificity (100%), while distinguishing
active disease from exposure or vaccination in
asymptomatic humans.15,16 These trials used
MPB64 extracted from liquid culture filtrate pro-
duced as a byproduct of growing bacille Calmette-
Gue´rin (BCG) Tokyo vaccine culture. Each patch
required approximately 1.5 l of BCG, thereby limiting
the potential for application to large-scale trials or
future deployment.5 However, MPT64, the protein
secreted by M. tuberculosis (rather than M. bovis), is
identical to MPB64 at the amino-acid level, and can
be produced at scale by purifying it from recombinant
Escherichia coli. At the time of the above clinical
trial, it was demonstrated that this recombinant (r)
MPT64 performed identically to MPB64 in a guinea
pig model, and so rMPT64, produced by Sequella Inc.
(Rockville, MD, USA) under Good Manufacturing
Practices, was used for the trial instead of MPB64.
Encouraged by these early findings, our study was
undertaken to assess the sensitivity and specificity of
the MPT64 patch test in the diagnosis of active TB
disease in a Phase III clinical trial.
METHODS
Study setting and design
This was a randomised, double-blind, placebo-
controlled, prospective study. Both healthy and
symptomatic patients were recruited from health care
establishments in Lima, Peru, from February to
December 2005. Group 1 consisted of 75 healthy
controls with no signs or symptoms of TB. Group 2
comprised 450 symptomatic individuals referred for
routine testing for TB by the National TB Control
Programme. All subjects underwent a comprehensive
diagnostic workup and received an active patch on
one arm and a placebo patch on the opposite arm, as
detailed below.
Study participants
Consecutive patients aged 18–65 years who provided
voluntary informed consent were included in the
study. Symptomatic patients either visited the clinic
directly or were referred from a feeder clinic for
investigation of respiratory symptoms, including TB
testing. Healthy controls were recruited if they
reported no human immunodeficiency virus (HIV)
infection or active TB within the previous 2 years, no
regular contact with a person with active TB andwere
sputum smear negative for acid-fast bacilli.
Study procedures
Demographic and clinical details were collected and
all subjects underwent a complete physical examina-
tion and chest X-ray. HIV testing was performed with
CD4 count for subjects known to be or newly
diagnosed with HIV infection. Two sputum samples
were collected and submitted for auramine fluores-
cence smear microscopy and liquid culture using the
microscopic observation drug susceptibility assay.17
Patches were applied, one to each forearm, and
patients returned 96 h later to have their patches
removed and read, and to undergo TST. Subjects
returned 48 h later for TST reading and a further
reading on day 6 of the two patch test sites. Follow-up
visits to repeat all procedures were originally planned
for months 3, 9, 12, 15 and 18.
The MPT64 patch
The MPT64 patches consisted of two component
parts: a Torii patch (Torii and Co, Tokyo, Japan) and
MPT64 antigen in phosphate-buffered saline (PBS)
solution. The previous MPB64 patch test studies had
used PBS and 0.005% Tween-80 as a buffer mixture;
however, as in the pilot studies in Peru mild skin
reactions to this buffer mixture alone were frequent,
Tween-80 was not used here. Placebo patches were
included so that reading would be blinded and, if a
non-specific reaction to the buffer and patch oc-
curred, a differential response could be recorded.
Placebo patches contained only the Torii patch and
buffer without MPT64. The patches were an adhesive
plaster with round, disc-shaped gauze 17 mm in
diameter and 1 mm thick at the centre. Immediately
before patch application, 100 ll of either MPT64
(total dose 150 lg) or placebo solution was applied to
the gauze of the Torii patch.
Randomisation was performed by Sequella Inc.,
which filled 10 tubes for each patient with either
MPT64 or control solution and randomly assigned a
label corresponding to an arm and subject number
(e.g., 1A/1B, 2A/2B). Solution A was applied to the
right arm patch, and Solution B to the left arm patch.
Research nurses preparing and applying the patches
were blinded to which solution contained the active
antigen. At the time of patch reading, staff were
blinded to TB status because of the time required to
conduct confirmatory culture tests. Patch results were
photographed and recorded as positive or negative
before knowing the TB status.
Patch reading
After removal of the patch at 4 days (if still adherent),
the patch sites were evaluated for erythema, vesicu-
lation, pruritus and induration subjectively by the
study nurse or physician, and were graded by the
study staff as part of an exploratory objective scale.
Participating subjects were also asked to evaluate the
responses, with particular attention given to any
differential reaction.
A randomized controlled trial in Peru 623
TB definition and assignment
Participants were assigned TB status from one of the
following: definite TB, probable TB, and not TB.
Definite TB was defined as a patient with any positive
microbiological test among two sputum microscopy
tests and two sputum cultures. Probable cases were
defined as individuals with chest X-ray findings
consistent with TB who started on TB medication
within 3 months of the initial visit, or cases with a
diagnosis of TBmade elsewherewithin 3months of the
initial visit, but without microbiological confirmation.
Data analyses
Analyses were conducted using definite active TB
cases only, and then using both definite and probable
cases. The main outcome measure of interest was
performance of the patch test in distinguishing active
TB from not TB, as measured by sensitivity and
specificity, according to assessment by field staff.
Patch test readings were designated ‘inconclusive’ if
there were cutaneous reactions on both forearms
without a qualitatively discernible difference (in other
words, the placebo patch provoked a reaction that
was qualitatively indistinguishable from the MPT64
patch) or if there was a markedly greater reaction on
the placebo site. These inconclusive patches were not
included in the analysis. The remaining patches were
designated ‘positive’ if only the active patch site
demonstrated a reaction, and ‘negative’ if neither
patch evoked any reaction (Appendix Figure A.1*).
Analysis of participant self-evaluations was included
to explore the feasibility of self-testing. An explor-
atory dermal reactivity scale was developed to
establish an objective cut-off value for positive tests.
Sample size was calculated using NQuery Advisor
5.0 (Statistical Solutions Ltd., Cork, Ireland) using
the exact test for a single proportion. All calculations
were done using a¼ 0.05 and assuming a two-sided
test. A target sample size of 90 definite TB cases was
chosen to provide 83% power for a lower confidence
limit for a sensitivity of .85%, assuming that true
sensitivity was 795%. Using local data, it was
assumed that only 20% of symptomatic individuals
would have bacteriologically confirmed TB; the
actual sample required was therefore 450 patients
undergoing investigation for TB. A sample size of 75
controls was chosen to provide 81% power for a
lower confidence limit for a specificity of .90%,
assuming that true specificity was 798%.
Statistical analysis was conducted using Stata for
Mac 13 (StataCorp, College Station, TX, USA). Basic
descriptive statistics were used to summarise contin-
uous and categorical data. Two-by-two tests of case
status and patch status were performed, followed by
receiver operating characteristic (ROC) curves of the
objective patch results to determine a cut-off value.
ROC regression was used to adjust for age, sex and
HIV status. Reporting was conducted in accordance
with Standards for Reporting of Diagnostic Accuracy
(STARD) guidelines.
Ethical review
The study protocol was approved by the institutional
reviewboards ofHammersmith andQueenCharlotte’s
&Chelsea Research Ethics Committee in London, UK,
and the Universidad Peruana Cayetano Heredia in
Lima. Institutional approval was granted by the
Direccio´n de Servicios de Salud (DISA) Lima Sur and
DISA Lima Este of the Peruvian Ministry of Health.
RESULTS
Baseline characteristics of study participants
Participant enrolment resulted in the recruitment of
457 subjects undergoing investigation for TB and 55
healthy, asymptomatic individuals. The mean age of
the symptomatic participants was 32.3 years, with
three quarters of participants aged 640 years and a
slight female preponderance (Table 1). HIV preva-
lence was low, at 3%; of these, 38% had a CD4 count
,200 cells/mm3. Although many patients also had
concurrent comorbidities, only two had a skin
condition that might have affected the patch re-
sponse. Loss to follow-up after 4 days was small, with
497 of 512 (97%) subjects returning for review.
Of 457 participants, 81 (18%) undergoing inves-
tigation for TB were classified as having definite TB
(Figure, A); 179 (39%) had definite or probable TB.
Sputum smear microscopy was positive in 51
participants (11%). All healthy, asymptomatic sub-
jects were classified as not having TB (Figure, B).
Criteria used for classification are shown in Table 2.
Performance characteristics
Applying the optimal conditions for performance
(outcome only including definite TB, trained staff
evaluation), the sensitivity and specificity in distin-
guishing active TB from no TB among individuals
being investigated for TB were respectively 26.7%
and 74.1% (Table 3). The use of different case
definitions or evaluators had no important effect
upon these parameters. Specificity among healthy
asymptomatic participants without TB was 68.4%
when evaluated by trained staff and 60.5% when
subjects self-evaluated.
Receiver operating characteristics of dermal reactivity
scale
There was a clear trend of decreasing frequency at
each level of the objective dermal reactivity scale
(Table 4), suggesting that the ordinal scale reflected
increasing reactivity. However, ROC curve analysis
* The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2018/
00000022/00000006/art00009
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did not reveal an obvious cut-off point for a positive
test result. The dermal scale, as reported after 4 days,
provided an area under the curve (AUC) value of
0.495 (95% confidence interval [CI] 0.425–0.565)
(Appendix Figure A.2). Other evaluation methods,
such as staff or participant evaluation, did not
perform better. Restricting analyses to include only
those subjects whose patches remained fully attached
or including probable TB cases did not have a
significant impact. Finally, adjustment for age, sex
and HIV status reduced the AUC to 0.421.
Positive patch tests
Of the 209 participants with one patch reaction
markedly stronger than the other, regardless of TB
status, the MPT64 patch was correctly identified as
the active patch in 102 (49%) subjects. In the
remaining 107 (51%), the test was erroneously
deemed as being positive on the basis of a stronger
reaction to the placebo patch.
Adverse events
Detailed data on all adverse events were collected.
Adverse events were recorded for 36% (184/512) of
participants. Each subjectwith an adverse reaction had
an average of 1.6 events, 11% of which were
characterised as serious: 16 subjects required hospi-
talisation, 3 died and 1 suffered significant or
persistent disability. However, none of these events
were considered related to the patch test. Of the 350
total events, only nine (3%) were deemed possibly or
probably related to the patch test. The most common
patch reactions were itching (n¼3, 33%) and allergic
dermatitis (n ¼ 2, 22%). Pain, discomfort, burning
sensation, infection at the patch site and pigmentation
disorder each occurred once. Finally, two subjects
reported a transient, sharp pain at the placebo site only.
Table 1 Demographic characteristics of the study population
Demographic
Subjects undergoing
investigation for TB
(n ¼ 457)
n (%)
Healthy,
asymptomatic subjects
(n ¼ 55)
n (%)
Age, years, mean 6 SD 32.3 6 11.8 29.4 6 6.7
Sex
Male 197 (43) 21 (38)
Female 260 (57) 34 (62)
Marital status
Single 353 (77) 43 (78)
Married 96 (21) 11 (20)
Other 8 (2) 1 (2)
Ethnicity
Mestizo 453 (99) 55 (100)
White 1 (0) —
Black 1 (0) —
Indian 2 (0) —
HIV-positive 14 (3) 0
CD4 count, cells/mm3 (n ¼ 12)
,100 1 (8) —
100–500 9 (75) —
.500 2 (16) —
TB¼ tuberculosis; SD¼ standard deviation; HIV¼ human immunodeficiency virus.
Table 2 Reference criteria for TB category assignment
Test
Under investigation for TB* Healthy, asymptomatic subjects
Definite
(n ¼ 81)
n (%)
Probable
(n ¼ 98)
n (%)
Not TB
(n ¼ 278)
n (%)
Definite
(n ¼ 0)
n (%)
Probable
(n ¼ 0)
n (%)
Not TB
(n ¼ 55)
n (%)
TST induration .10 mm 73 (90) 84 (86) 151 (54) — — 40 (73)
Chest radiograph
Normal 4 (5) 22 (22) 198 (71) — — 52 (95)
Abnormal at 3 months 0 4 (18) 0 — — 0
Abnormal, consistent with TB 76 (94) 56 (57) 49 (18) — — 0
Abnormal, not TB 1 (1) 20 (20) 30 (11) — — 3 (5)
Sputum smear-positive (at least one) 51 (63) 0 0 — — 0
Sputum culture-positive (at least one) 80 (99) 0 0 — — 0
*10 subjects were lost to follow-up between their baseline investigations and having their patches read; 2 were classified as having definite TB, 1 was classified as
probable TB and 7 were classified as not TB.
TB¼ tuberculosis; TST¼ tuberculin skin test.
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DISCUSSION
The key finding of this double-blind, placebo-
controlled trial was that the MPT64 patch test was
not able to distinguish patients with active TB from
those without TB among symptomatic individuals
undergoing investigation for TB. Two fundamental
problems contributed to this outcome: a high
background dermal reaction to the placebo patch
and the lack of a consistent differential MPT64
reaction among TB patients.
The main analysis was conducted using efficacy
rather than effectiveness because of a concern about
reactions to placebo patches recorded in a pilot trial
(data not shown). Measuring efficacy removed cases
where a positive reaction may have been the result of
irritation or reaction to the buffer. Despite this
advantage, the test performed indistinguishably from
random guessing. Results were unchanged by TB
definition, reader training or after adjustment for age,
sex and HIV status.
These results differ significantly from smaller trials
conducted elsewhere,15,16 despite similar procedures
and patch reagents. Although the MPT64 dose
delivered here was higher than in previous trials, data
from 2003 demonstrated that higher doses increased
the reaction, so this was unlikely to have caused a null
result.15 Furthermore, dosing differences would not
explain the high number of positive placebo patches.
The biggest possible source of discrepancy was the
difference in protein source. rMPT64 is identical to
MPB64 at the amino-acid level, and has also been
shown to induce an identical delayed-type hypersen-
sitivity reaction in guinea pigs.5 This makes differ-
ences in reaction due to the protein unlikely.
Table 3 Sensitivity and specificity analysis (evaluable
participants only)
Case definition
Under investigation for TB (n ¼ 342)*
Staff
evaluation
Participant
evaluation
Sensitivity
%
Specificity
%
Sensitivity
%
Specificity
%
Definite TB 26.7 74.1 20.0 72.7
Definite or
probable TB 23.9 72.6 24.6 73.1
Smear-positive TB† 24.3 73.8 16.2 72.8
Healthy asymptomatic (n ¼ 38)‡
Non-case — 68.4 — 60.5
*105 inconclusive patches were excluded from this total.
† As per Nakamura 2003.15
‡ 17 inconclusive patches were excluded from this total.
TB¼ tuberculosis.
Figure A) STARD flowchart for subjects undergoing investiga-
tion for TB (patch test reading by a trained research nurse). * 70
participants were missing one or more patches at the time of
follow-up. These were included in the final analysis as the test
could be read from the dermal reaction before the patchwas lost.
A separate analysis (not shown) found no difference between
including only fully attached patches and including everyonewho
returned after 4 days. † Placebo patch reaction (n¼97), reaction
in both patches (n ¼ 8). B) STARD flowchart for asymptomatic
healthy individuals (patch test reading by a trained research
nurse). * 7 participants were missing one or more patches at the
time of follow-up. These were included in the final analysis as the
test could still be read from the dermal reaction before the patch
was lost. A separate analysis (not shown) showed no difference
between including only fully attached patches and including
everyonewho returned after 4 days. † Placebo patch reaction (n¼
10), reaction in both patches (n¼7). TB¼ tuberculosis; STARD¼
Standards for Reporting of Diagnostic Accuracy.
Table 4 Dermal reactivity scale and results (subjects under
investigation for tuberculosis only, n¼ 397)*
Dermal reaction
Active
n (%)
Placebo
n (%)
None 223 (56) 224 (57)
Minimal erythema 69 (17) 58 (15)
Definite erythema 27 (7) 27 (7)
Vesicular eruption 38 (10) 46 (12)
Vesicular eruption and minimal erythema 24 (6) 27 (7)
Vesicular eruption and definite erythema 13 (3) 12 (3)
Erythema and papules 2 (1) 2 (1)
Definite oedema 1 (0) 0
*Only patches that remained attached are included.
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However, further analyses of the differences between
MPT64 and rMPT64 have been conducted by
Sequella since we completed this study. It was
determined that the quaternary structure of the
protein was preserved and that there were no detected
post-translational modifications in either sample,
although methylation was not investigated. However,
two other molecules, one very small, the other 14
kDa, were found in the original sample of MPT64
tested by Nakamura et al. This sample also demon-
strated significant limulus amoebocyte lystate activ-
ity, which could mean it had endotoxin-like activity
or that it was contaminated with lipopolysaccharide
at some point during or after purification. A novel
batch of MPT64 prepared in the same manner as the
original had neither the endotoxin-like activity nor
the two smaller molecules; this novel preparation of
MPT64 has not yet been tested clinically, but the
results could point to novel patch test reagent targets.
An explanation is also needed for the frequent
positive reactions to placebo patches, which signifi-
cantly undermined any likelihood thatMPT64 patches
would helpfully differentiate TB fromnon-TB patients.
All previous studies were conducted in the Philippines,
and the significant ethnic differences might underlie
different immunological responses, although, if this is
found to be the case, such a phenomenon would have
major implications for the global development of an
immunodiagnostic of this type.
The present study had important limitations that
affected the generalisability of the results. These
limitations were primarily related to the population
sampled. Almost everyone in the study was mestizo,
which potentially limited the results to that specific
subpopulation, even within Peru. However, far more
participants were recruited into the present study
than all previous studies of MPT64 patch tests
combined, and the efficacy of the patch test was able
to be thoroughly examined using randomised alloca-
tion, blinded reading and parallel placebo patches.
Various alternative readers and reading scores were
explored and patch test findings were consistently
disappointing, with important implications for future
research into MPT64 diagnostic tools.
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Figure A.1 Examples of A) a positive, B) an indeterminate and C) a negative patch test.
Figure A.2 Comparison of receiver operating characteristic curves for various evaluation
methods (participants under investigation for tuberculosis only, n ¼ 342).* * 105 inconclusive
patches were excluded from this total.
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R E´ S U M E´
CONT EX T E : Il manque toujours des tests de diagnostic
fiables et peu couˆteux de la tuberculose (TB) active.
Tester les re´ponses immunitaires aux prote´ines se´cre´te´es
par Mycobacterium tuberculosis, comme MPT64,
pourrait eˆtre une option de diagnostic.
OB J E C T I F : Evaluer la sensibilite´ et la spe´cificite´ d’un
patch test base´ sur MPT64 pour le diagnostic de la TB
active.
S C H E´M A : Cette e´tude prospective randomise´e, en
double aveugle, contre placebo, a` Lima, Pe´rou, a
implique´ 55 te´moins en bonne sante´ et 457 individus
symptomatiques re´fe´re´s pour un test TB de routine par le
Programme National de lutte contre la TB. Tous les
sujets ont eu un bilan diagnostic complet et ont rec¸u un
patch actif sur un bras et un patch placebo sur le bras
oppose´ ; la lecture a e´te´ faite apre`s 4 jours.
R E´ S U LTAT S : Des participants symptomatiques, 81
(18%) ont e´te´ classe´s comme ayant une TB certaine,
tandis que 98 autres (21%) avaient une TB probable.
Les patch tests ont eu la meˆme performance dans les
deux groupes, avec une sensibilite´ de 27% et une
spe´cificite´ de 74%. La zone sous la courbe de la
fonction d’efficacite´ du re´cepteur a e´te´ de 0,495
(IC95% 0,425–0,565).
CONC LU S I ON : Le patch MPT64 n’a e´te´ ni sensible ni
spe´cifique dans la de´tection de la TB active, en contraste
avec la litte´rature existante. Etant donne´ le potentiel de
ce test, comprendre les diffe´rences potentielles de la
source de prote´ines ou les facteurs ge´ne´tiques sous-
jacents devrait eˆtre davantage explore´.
R E S UM E N
CONT EX TO: En la actualidad no se dispone de me´todos
diagno´sticos efectivos y de bajo coste para la enfermedad
activa por tuberculosis (TB). Analizar la respuesta
inmune a proteı´nas secretadas por Mycobacterium
tuberculosis, como la MPT64, podrı´a ser una opcio´n
diagno´stica.
OB J E T I VO: Evaluar la sensibilidad y especificidad de
una prueba de parche que utiliza MPT64 para el
diagno´stico de la enfermedad activa por TB.
D I S E N˜O: Este estudio prospectivo, aleatorizado, doble
ciego, controlado con placebo en Lima, Peru´, incluyo´ a
55 controles sanos y 457 individuos sintoma´ticos
remitidos al Programa Nacional de control de la TB
para pruebas rutinarias de deteccio´n de TB. Todos los
sujetos fueron sometidos a un examen diagno´stico
exhaustivo y recibieron un parche activo en un brazo y
un parche de placebo en el brazo opuesto, los cuales
fueron leı´dos despue´s de 4 dı´as de colocados.
R E SU LTADOS: De los participantes sintoma´ticos, 81
(18%) fueron diagnosticados como TB definitiva,
mientras que 98 (21%) como TB probable. Los
resultados de la prueba del parche fueron similares en
ambos grupos, obteniendo una sensibilidad del 27% y
una especificidad del 74%. El a´rea bajo la curva
caracterı´stica operativa del receptor fue 0,495 (IC95%
0,425–0,565).
C O N C L U S I O N E S: En contraste con la literatura
existente, el parche MPT64 no fue sensible ni
especı´fico para detectar TB activa. Dado el potencial
de la prueba, se deberı´a explorar con ma´s detalle las
potenciales diferencias en la fuente de la proteı´na y los
factores gene´ticos subyacentes.
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